Actelion close to sealing Ceptaris deal as US approves drug

ZURICH Mon Aug 26, 2013 1:29am EDT

Related News

Related Topics

ZURICH Aug 26 (Reuters) - Swiss biotech firm Actelion said an important condition for its acquisition of privately-held Ceptaris was met with Ceptaris gaining U.S. approval for its Valchlor gel.

The companies are now completing further closing conditions before the acquisition is concluded, Actelion said in a statement on Monday.

The U.S. health regulator FDA has approved Ceptaris Therapeutics' topical drug for treatment of a rare form of non-Hodgkin's lymphoma, Actelion said.

The Allschwil-based company said in July it already paid Ceptaris $25 million and will pay another $225 million when the deal closes.

(Reporting by Alice Baghdjian)

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.